PRME Prime Medicine, Inc.

Nasdaq primemedicine.com


$ 3.63 $ -0.27 (-6.92 %)    

Thursday, 20-Nov-2025 14:51:13 EST
QQQ $ 589.52 $ -22.15 (-3.62 %)
DIA $ 459.77 $ -6.91 (-1.48 %)
SPY $ 655.93 $ -16.97 (-2.52 %)
TLT $ 89.22 $ 0.23 (0.26 %)
GLD $ 375.29 $ 0.11 (0.03 %)
$ 3.72
$ 3.90
$ 3.61 x 1,363
$ 3.61 x 200
$ 3.60 - $ 4.04
$ 1.11 - $ 6.94
5,568,196
na
nm
$ 2.20
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-10-2024 03-31-2024 10-Q
8 03-01-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-neutral-on-prime-medicine-lowers-price-target-to-425

Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and lowers the price target from $...

 chardan-capital-maintains-buy-on-prime-medicine-lowers-price-target-to-9

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

 chardan-capital-maintains-buy-on-prime-medicine-lowers-price-target-to-10

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

 prime-medicine-q2-eps-041-misses-039-estimate-sales-1115m-beat-750000k-estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0....

 prime-medicine-announces-proposed-public-offering-of-common-stock-no-size-or-amount-disclosed

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time cura...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION